{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-22-000037","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.269566+00:00","generated_at":"2026-06-22T15:51:58.165112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVS Q3 GAAP loss $(2.60) on opioid/LTC charges; adj. EPS $2.09 beat; raises full-year adj. guidance","bullets":["Total revenues $81.2B (+10.0% YoY); GAAP diluted loss per share $(2.60) vs $1.20 EPS prior year.","GAAP results include $5.2B pre-tax opioid litigation charge and $2.5B pre-tax loss on LTC business held for sale.","Adjusted EPS of $2.09 vs $1.97 prior year; full-year adj. EPS guidance raised to $8.55-$8.65 from $8.40-$8.60.","Full-year GAAP EPS guidance lowered to $3.12-$3.22 from $7.23-$7.43 due to the charges.","Agreed to acquire Signify Health for $30.50/share (~$8B total); repaid $2.6B debt and paid $726M dividends in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-22-000037","json":"https://secwatch.observer/filing/0000064803-22-000037.json","markdown":"https://secwatch.observer/filing/0000064803-22-000037.md","text":"https://secwatch.observer/filing/0000064803-22-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/0000064803-22-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/cvs-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T15:51:58.165112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35a71f123d4af5d170645bccaacc4d154b121913","claim":"CVS HEALTH Corp reported three months ended September 30, 2022 results: revenue $81.2 billion, EPS $(2.60). Guidance raised.","evidence_excerpt":"Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2022. THIRD QUARTER RESULTS KEY FINANCIAL DATA • Total revenues increased to $81.2 billion, up 10.0% compared to prior year • GAAP loss per share of $(2.60), inclusive of $5.2 billion pre-tax opioid litigation charges and a $2.5 billion pre-tax loss on assets held for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/0000064803-22-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Revenue","value":"$81.2 billion"},{"label":"EPS","value":"$(2.60)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c8d5bbbb85f8c62deb46f48db4a66c68f990201c","claim":"CVS HEALTH Corp reported 2022 (year-to-date) results: revenue $238.6 billion, EPS $1.40. Guidance raised.","evidence_excerpt":"Total revenues increased to $238.6 billion, up 10.7% compared to prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/0000064803-22-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022 (year-to-date)"},{"label":"Revenue","value":"$238.6 billion"},{"label":"EPS","value":"$1.40"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}